ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6066 articles about ACCESSWIRE
-
Abivax 2022 Financial Communication Calendar
1/25/2022
Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases and cancer, publishes its 2022 financial communication calendar.
-
Significantly Reduced Tumor Growth with Tumorad(R) According to New Preclinical Results
1/25/2022
Spago Nanomedical AB announced new results which show that the company's leading candidate drug Tumorad significantly reduces tumor growth and prolongs survival in a preclinical model for colorectal cancer.
-
Melzi Surgical Appoints Financial Industry Executive, Michael Layman to Board of Directors
1/25/2022
Melzi Surgical announced today the appointment of Michael Layman to its Board of Directors.
-
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
1/24/2022
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics.
-
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
1/24/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 16/713,052 entitled, "Ready to Use Diclofenac Packs.".
-
Biotricity Receives FDA 510(k) Clearance for its Biotres Cardiac Monitoring Device
1/24/2022
Biotricity, Inc., a medical diagnostic and consumer healthcare technology company, reported it has received 510 clearance from the U.S. Food and Drug Administration for its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.
-
XPhyto Provides Update on Integration of 3a-diagnostics GmbH
1/24/2022
XPhyto Therapeutics Corp. is pleased to provide an update on the integration of 3a-diagnostics GmbH into XPhyto's German operations.
-
Senzime signs Exclusive US Service Agreement with Mercury Medical(R) for their TetraGraph(R) Quantitative Neuromuscular Monitor
1/24/2022
Senzime has selected Mercury Medical as their exclusive United States provider of Biomedical repair and maintenance services for their TetraGraph product line.
-
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
1/24/2022
NeoGenomics, Inc. announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.
-
9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors
1/24/2022
9 Meters Biopharma, Inc. announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 17/239,056 is allowed.
-
XVIVO’s Kidney Assist Transport Receives 510(k) Clearance by US FDA, Which Is XVIVO’s First Regulatory Cleared Product for Abdominal Transplantation in the US
1/21/2022
XVIVO Perfusion AB XVIVO proudly announces that the US Food & Drug Administration has granted clearance for Kidney Assist Transport.
-
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
1/21/2022
Aptevo Therapeutics Inc. today announced that founding chairman of the board, Fuad El-Hibri, has announced his retirement effective April 1, 2022. The Company also announced that long-time board member and vice chairman John E. Niederhuber, M.D., will assume the chairmanship, effective April 1, 2022.
-
Melzi Surgical to Present at the Virtual Investor 2022 Top Picks Conference
1/21/2022
Melzi Surgical, a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced that Reid Rutherford, Co-Founder and CEO will participate in the JTC Virtual Investor 2022 Top Picks Conference on Wednesday, January 26, 2022 at 1:00 PM ET.
-
Angle PLC Announces Potential in Immunotherapy Treatment Selection
1/21/2022
ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in ovarian cancer patients using the Parsortix® system.
-
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference
1/20/2022
enVVeno Medical Corporation announced that Robert Berman, Chief Executive Officer of enVVeno, will present at the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 1:00 PM ET.
-
Champions Oncology Announces a Partnership with Fannin Innovation to Jointly Develop Therapeutic Raptamer Drug Conjugates
1/20/2022
Champions Oncology, Inc. announced today a therapeutic co-development partnership with Fannin Innovation Studio.
-
Viewpoint Molecular Targeting(R) to Present at the Virtual Investor 2022 Top Picks Conference
1/20/2022
Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced that Frances L. Johnson, MD, Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 11:00 AM ET.
-
Clairvoyant Therapeutics Receives Approval in Canada to Initiate a World-leading Psilocybin Trial for Treatment of Alcohol Use Disorder
1/20/2022
Clairvoyant Therapeutics is pleased to announce it has received Health Canada approval to initiate a Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) (formerly called alcoholism).
-
Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022
1/19/2022
Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 for the treatment of hepatocellular carcinoma, to be presented at the ASCO GI Cancers Symposium on January 20-22, 2022.
-
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
1/19/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced enhancements to its Expanded Access and Right to Try programs.